



ASX ANNOUNCEMENT

16 April 2024

IDT Secures contract with Sanofi Australia

Highlights:

- Sanofi and IDT complete a Master Service Agreement to support the cGMP manufacture of Sanofi's global mRNA assets under development.
- The contract entails collaboration between IDT and Sanofi to advance mRNA-based vaccine formulation, development, and manufacture clinical trial material, targeting various indications.
- Revenue generated from the contract falls under IDT's Advanced Therapies (AT) vertical, aligning with the company's strategic vision to pursue higher-value, complex formulations.

IDT Australia Limited (ASX: IDT) (IDT Australia) is pleased to announce that it has entered into a Master Service Agreement with Sanofi, an innovative global healthcare company, to support the preclinical formulation development and cGMP manufacture of Sanofi's messenger RNA (mRNA) for its translational clinical program. The agreement allows flexibility for Sanofi to choose services from IDT Australia and allows for follow-on work packages. The value of the services to be provided under the initial order, which is nearing finalisation, under the Master Service Agreement is estimated to be between AUD \$3 to 3.5 million (excluding costs relating to storage, shipping and any equipment purchase).

Under the terms of the Master Service Agreement, IDT Australia will collaborate with Sanofi to advance the formulation, and manufacture current Good Manufacturing Practice (cGMP) novel mRNA-based vaccines for clinical trials targeting a range of indications to support unmet medical needs.

The revenue from the contract falls under IDT Australia's Advanced Therapies (AT) vertical and the contract with Sanofi supports the Company's strategic vision to pursue higher-value contracts that require more complex formulations. IDT Australia has one of the few aseptic sterile fill (injectables) facilities to complete mRNA downstream processing in Asia Pacific.

Paul McDonald, the Chief Executive Officer of IDT Australia, commented:

"Through design and synthesis of novel molecules to novel formulations, IDT Australia is committed to the translation of medicine from bench to patient. We are constantly and actively investing in our capabilities to deliver complex formulation development of novel advanced therapies.

"We are thrilled to secure an agreement with Sanofi, progressing their groundbreaking science into cGMP manufacture to deliver mRNA product solutions to unmet medical needs. This collaboration with Sanofi underscores IDT Australia's unique expertise and world-class facilities while reinforcing our position as a trusted partner in the global pharmaceutical industry."

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

IDT Australia Limited
ABN 66 006 522 970
45 Wadhurst Drive
Boronia, Victoria 3155, Australia
T +61 3 9801 8888
W www.idtaus.com.au



Ends.../

Authorised by the Board of Directors of IDT Australia Limited.

For investor and media enquiries, please contact:

Brendon Lau

E: brendon@vantagepointpartners.com.au

M: +61 409 341 613

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia's beliefs, assumptions, and expectations and on information currently available to IDT Australia.

All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.